|Articles|September 28, 2012

Yervoy – References pg 1

References:1. YERVOY package insert. Princeton, NJ: Bristol-Myers Squibb; 2011.2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med.2010;363(8);711-723.

References:
1. YERVOY package insert. Princeton, NJ: Bristol-Myers Squibb; 2011.
2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med.2010;363(8);711-723.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

November 3rd, 2026

Sac-TMT Earns FDA Priority Review in Pretreated Endometrial Cancer

The FDA set a June 15, 2027, target action date for sacituzumab tirumotecan in endometrial cancer previously treated with platinum chemotherapy and immunotherapy.

Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.

November 3rd, 2026

What Early Career Physicians Need to Know About Building New Radiation Oncology Service Lines

Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.

November 3rd, 2026

Monitoring Delayed Immune-Related Adverse Events With Adjuvant Durvalumab

Sunnie Kim, MD, outlined how she monitors for endocrine, renal, pulmonary, and other immune-related adverse events during adjuvant durvalumab.

Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.

November 2nd, 2026

How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?

Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.

November 2nd, 2026

Expanding Access to Advanced Radiation Services Across a Network

Parul N. Barry, MD, FACRO, discussed extending advanced radiation services to satellite sites and offered guidance for early career physicians building new programs.